Cetera Investment Advisers
ZVRA icon

Cetera Investment Advisers’s Zevra Therapeutics ZVRA Stock Holding History

Cetera Investment Advisers’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10,973
Closed -$63.6K – 3865
2024
Q1 		$63.6K Buy
+10,973
New +$67.5K ﹤0.01% 3549

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

Cetera Investment Advisers's ZVRA Position: Q2 2024 in Review

Cetera Investment Advisers sold out of Zevra Therapeutics (ZVRA) in Q2 2024, closing a stake of 10,973 shares — an estimated $63.6K sold.

Cetera Investment Advisers first reported a position in ZVRA in Q1 2024 and held it in 1 quarter. The position peaked at $63.6K in Q1 2024. 93 funds tracked by Wall St. Rank hold ZVRA as of Q2 2024.

  • Cetera Investment Advisers reported no remaining Zevra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cetera Investment Advisers sold 10,973 Zevra Therapeutics shares in Q2 2024, an estimated $63.6K.
  • Cetera Investment Advisers first reported a position in Zevra Therapeutics in Q1 2024 and held it in 1 quarter.
  • Cetera Investment Advisers's Zevra Therapeutics position peaked at $63.6K in Q1 2024.
  • 93 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2024.

Based on Cetera Investment Advisers's 13F filing for Q2 2024, filed 22 Aug 2024.